Ionis Pharmaceuticals Inc (IONS): Cost of Revenue
$15.91M
Year ended 2025-12-31
$16.02M
Trailing 12 months to 2026-06-30
+4.1%
3-year compound annual growth
+5.9%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $15.91M | +41.9% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $11.21M | +22.8% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $9.13M | -35.3% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $14.12M | +30.2% | 2025-02-19, From 2022-01-01 |
| 2021-12-31 | $10.84M | -9.2% | 2024-02-21, From 2021-01-01 |
| 2020-12-31 | $11.95M | +172.5% | 2023-02-22, From 2020-01-01 |
| 2019-12-31 | $4.38M | +140.9% | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | $1.82M | n/a | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | $0 | n/a | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $0 | n/a | 2019-03-01, From 2016-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Ionis Pharmaceuticals Inc (IONS) | 2025-12-31 | $15.91M | +41.9% |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2024-12-31 | $6.23M | n/a |
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $198.34M | +26.5% |
| Acadia Pharmaceuticals Inc (ACAD) | 2025-12-31 | $89.00M | +8.7% |
| Prestige Consumer Healthcare Inc. (PBH) | 2026-03-31 | $493.13M | -2.0% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $317.31M | +24.9% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $12.98M | +19.3% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $326.20M | -52.1% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $149.75M | -12.1% |
Compare IONS, MDGL, HRMY, ACAD side by side · Screen every company in Pharmaceutical Preparations ↗